Skip to main content
Sino Biopharmaceutical Limited logo

Sino Biopharmaceutical Limited — Investor Relations & Filings

Ticker · 1177 ISIN · KYG8167W1380 LEI · 529900LPR4ADFEJAR786 HKEX Manufacturing
Open in API
Filings indexed 64 across all filing types
Latest filing 2026-05-27 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 1177

About Sino Biopharmaceutical Limited

http://www.sinobiopharm.com

Sino Biopharmaceutical Limited is a research and development pharmaceutical conglomerate specializing in the discovery, production, and commercialization of a diverse portfolio of pharmaceutical products, encompassing both chemical drugs and biologics. The company maintains a leading market presence across four primary therapeutic fields: Oncology, Hepatology, Respiratory, and Cardiovascular/Cerebrovascular diseases. Its core strategy centers on innovation, leveraging advanced R&D platforms, including small interfering RNA (siRNA) technology and specialized oncology treatments. The firm actively pursues strategic mergers and acquisitions to integrate new technologies, accelerate its layout in major chronic diseases, and drive long-term growth.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL DATA ON KYLO-0603 PRESENTED AT EASL 2026
Regulatory Filings Classification · 60% confidence The document is a voluntary corporate announcement by Sino Biopharmaceutical Limited reporting Phase I clinical trial data for a drug candidate. It is not a financial report (10-K, IR), earnings release, board/management change, capital update, ESG report, dividend notice, or any other specific category. It is a general regulatory/market announcement without substantive financial statements or share actions. Therefore it falls into the fallback category ‘Regulatory Filings’ (RNS).
2026-05-27 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 95% confidence The document is a Hong Kong Stock Exchange Next Day Disclosure Return (Form FF305) detailing changes in issued and treasury shares, including detailed share repurchase transactions and related balances. It is a regulatory disclosure of the company’s own share repurchases, fitting the definition of a Transaction in Own Shares.
2026-05-22 English
VOLUNTARY ANNOUNCEMENT - DATA FROM TWO CLINICAL STUDIES OF M701 "CD3/EpCAM BISPECIFIC ANTIBODY" PRESENTED AT 2026 ASCO
Regulatory Filings Classification · 75% confidence The document is a voluntary announcement filed with the Hong Kong Exchange regarding clinical trial data presentations at ASCO. It does not contain financial statements, management discussion or formal reports, nor does it relate to shares, dividends, M&A or governance changes. It is essentially a press‐release style corporate disclosure. It therefore falls under the fallback category for general regulatory announcements that do not fit any specific filing type: Regulatory Filings (RNS).
2026-05-22 English
VOLUNTARY ANNOUNCEMENT - ZONGERTINIB, A HER2 TYROSINE KINASE INHIBITOR, APPROVED FOR FIRST-LINE TREATMENT OF HER2-MUTANT NON-SMALL CELL LUNG CANCER
Regulatory Filings Classification · 15% confidence The document is a corporate “Voluntary Announcement” about a drug approval by the NMPA, containing no financial results, management changes, share transactions, or meeting materials. It does not fit into any specific category like earnings release, M&A, financing activity, or report itself. Therefore it is classified under the fallback “Regulatory Filings” category for general regulatory or compliance announcements (RNS).
2026-05-21 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 90% confidence The document is a Form FF305 “Next Day Disclosure Return” required by the Hong Kong Stock Exchange, detailing changes in issued shares, treasury shares, and a detailed repurchase report (share buybacks) including dates, number of shares repurchased, prices, and confirmation. This is not an earnings release, management report, or proxy statement but a routine regulatory disclosure of the company’s own share transactions. According to the filing taxonomy, this falls squarely under “Transaction in Own Shares” (POS).
2026-05-20 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares, treasury shares, share buybacks, and on-market sales of treasury shares. It references specific rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) governing disclosures of share repurchases and changes in issued shares. The content includes detailed tables of shares repurchased, repurchase prices, dates, and confirmations that repurchases were made in accordance with exchange rules. There is no indication that this is a full financial report, earnings release, or management discussion. Instead, it is a regulatory disclosure about share repurchase activities and changes in share capital. This fits the definition of a 'Transaction in Own Shares' filing, which reports the company's buyback or sale of its own shares. The document length and detail confirm it is the report itself, not just an announcement of a report publication or a certification. Therefore, the appropriate classification is POS (Transaction in Own Shares).
2026-05-19 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.